{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:46:08Z","timestamp":1790347568286,"version":"4.1.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The detection of measurable residual disease (MRD) is the strongest predictor of relapse in acute lymphoblastic leukemia (ALL). Using inotuzumab ozogamicin in the setting of MRD may improve outcomes. Patients with ALL in first complete remission (CR1) or beyond (CR2+) with MRD \u2265 1\u00a0\u00d7 10\u22124 were enrolled in this phase 2 trial. Inotuzumab was administered at 0.6 mg\/m2 on day 1 and 0.3 mg\/m2 on day 8 of cycle 1, then at 0.3 mg\/m2 on days 1 and 8 of cycles 2-6. Twenty-six consecutive patients with a median age of 46 years (range, 19-70 years) were treated. Nineteen (73%) were in CR1 and seven (27%) in CR2+; 16 (62%) had Philadelphia chromosome\u2013positive ALL. Fifteen (58%) had baseline MRD \u2265 1\u00a0\u00d7 10\u22123. A median of 3 cycles (range, 1-6) were administered. Eighteen (69%) patients responded and achieved MRD negativity. After a median follow-up of 24 months (range, 9-43), the 2-year relapse-free survival rate was 54% and the 2-year overall survival rate was 60% in the entire cohort. Most adverse events were low grade; sinusoidal obstruction syndrome was noted in 2 patients (8%). In summary, inotuzumab ozogamicin resulted in favorable survival, MRD negativity rates, and safety profiles for patients with ALL and MRD-positive status. This study was registered at www.ClinicalTrials.gov as #NCT03441061.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2023022330","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T20:01:13Z","timestamp":1698264073000},"page":"417-421","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":52,"title":["Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission"],"prefix":"10.1182","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-2567","authenticated-orcid":false,"given":"Jayastu","family":"Senapati","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0114-8384","authenticated-orcid":false,"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1875-2986","authenticated-orcid":false,"given":"Jeffrey","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology and Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Hematopathology and Molecular Diagnostics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-7937","authenticated-orcid":false,"given":"Yesid","family":"Alvarado","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3516-0966","authenticated-orcid":false,"given":"Xuemei","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4196","authenticated-orcid":false,"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Garris","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"7","key":"2024020116213812600_bib1","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol"},{"issue":"2","key":"2024020116213812600_bib2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2141.2008.07185.x","article-title":"Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD study","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"1","key":"2024020116213812600_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11912-017-0565-x","article-title":"Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat it","volume":"19","author":"Short","year":"2017","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2024020116213812600_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ajh.25338","article-title":"Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts","volume":"94","author":"Short","year":"2019","journal-title":"Am J Hematol"},{"issue":"14","key":"2024020116213812600_bib5","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2024020116213812600_bib6","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.26634","article-title":"Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10\u22124 and higher","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"issue":"2 pt A","key":"2024020116213812600_bib7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"67","author":"Shor","year":"2015","journal-title":"Mol Immunol"},{"issue":"14","key":"2024020116213812600_bib8","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"2024020116213812600_bib9","doi-asserted-by":"crossref","first-page":"106283","DOI":"10.1016\/j.leukres.2019.106283","article-title":"Impact of minimal residual disease status in patients with relapsed\/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial","volume":"88","author":"Jabbour","year":"2020","journal-title":"Leuk Res"},{"issue":"suppl 1","key":"2024020116213812600_bib10","doi-asserted-by":"crossref","first-page":"11698","DOI":"10.1182\/blood-2022-170049","article-title":"Improved outcomes with low-dose inotuzumab and mini-hyper-CVD followed by blinatumomab consolidation in relapsed-refractory acute lymphoblastic leukemia: results of a phase II study","volume":"140","author":"Haddad","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024020116213812600_bib11","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1182\/blood-2022-157937","article-title":"Gimema ALL2418: interim analysis of a phase IIa study of feasibility and effectiveness of inotuzumab ozogamicin in adult patients with B-cell acute lymphoblastic leukemia with positive minimal residual disease before any hematopoietic stem cell transplantation","volume":"140","author":"Marconi","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2024020116213812600_bib12","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"issue":"11","key":"2024020116213812600_bib13","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"G\u00f6kbuget","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/417\/2210910\/blood_bld-2023-022330-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/5\/417\/2210910\/blood_bld-2023-022330-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T16:22:07Z","timestamp":1706804527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/5\/417\/498427\/Phase-2-study-of-inotuzumab-ozogamicin-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023022330","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}